Medicine and Health
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
This analysis of the SELECT trial reveals how semaglutide significantly aids weight loss in patients with established cardiovascular disease and obesity, achieving a remarkable mean reduction of 10.2% over 4 years. Conducted by a team of experts including Donna H. Ryan and Ildiko Lingvay, this groundbreaking research underscores the clinical effectiveness of semaglutide in various demographics.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.
